Table 1.
Clinical and demographical characteristics of patients with AGL included in the study
| All patients with AGL (n = 40) | Reference range | |
|---|---|---|
| AGL variety, n (%) | — | |
| Autoimmune | 22 (55) | |
| Panniculitis | 5 (12.5) | — |
| Panniculitis plus autoimmune | 10 (25) | — |
| Idiopathic | 3 (7.5) | — |
| Female, n (%) | 30 (75) | — |
| Age (years), mean (SD) | 28.5 (18.2) | — |
| Lipodystrophy onset (years), median (IQR) | 6 (3–13.5) | — |
| Time with lipodystrophy (years), median (IQR) | 11.5 (6–17.2) | — |
| BMI (kg/m2), mean (SD) | 19.6 (3.5) | 18–25 |
| Percent total fat, mean (SD) | 11.6 (5.3) | 27.2–33.3 |
| Acanthosis, n (%) | 16 (40) | — |
| Glucose (mg/dL), median (IQR) | 106 (85.9–148.3) | 74–106 |
| Insulin (μU/mL), median (IQR) | 43.2 (13.3–95.5) | 3–25 |
| Diabetes, n (%) | 28 (70) | — |
| HbA1c (mmol/mol), median (IQR) | 42 (36–63) | 20–42 |
| HOMA-IR, median (IQR) | 12.4 (2.9–32.2) | 0–2.6 |
| Triglycerides (mg/dL), median (IQR) | 163.5 (122–352) | <150 |
| Total cholesterol (mg/dL), median (IQR) | 148 (128–193) | <200 |
| HDL (mg/dL), median (IQR) | 28 (22–33.5) | >40 |
| Leptin at baseline (ng/mL), median (IQR) | 1.3 (0.5–2.7) | <12 ng/mL in women, <8 ng/mL in men |
| Metreleptin treatment, n (%) | 23 (57.5) | — |
| Leptin after metreleptin treatment (ng/mL), median (IQR) | 9.6 (1.9–69.2) | <12 ng/mL in women, <8 ng/mL in men |
| Fatty liver, n (%) | 31 (77.5) | — |
| ALT (IU/L), median (IQR) | 39.5 (25.3–86.5) | <35 |
| AST (IU/L), median (IQR) | 30.5 (21–53.3) | <40 |
| IgG (mg/dL), median (IQR) | 1,077 (948.5–1,333) | 725–1,900 |
| IgA (mg/dL), median (IQR) | 151.5 (109–232.5) | 50–340 |
| IgM (mg/dL), median (IQR) | 89.3 (52.5–133.5) | 45–280 |
| C3 (mg/dL), median (IQR) | 125.4 (109.2–139) | 75–135 |
| C4 (mg/dL), median (IQR) | 17.4 (12.6–23.9) | 14–60 |
| Autoimmunity*, n (%) | 32 (80) | — |
| Immunosuppressant treatment, n (%) | 10 (25) | — |
Data are reported as mean ± SD, median (IQR), or absolute number (percentage).
HOMA-IR, HOMA of insulin resistance.
*
The presence of autoantibody positivity and/or autoimmune disease.